Education
About Us
Working with TipRanks
Follow Us
Finch Therapeutics Group, Inc. (FNCH)
:FNCH
RESEARCH TOOLSreports
Total Valuation
Finch Therapeutics Group has a market cap or net worth of $20.23M. The enterprise value is $12.98M.
Market Cap$20.23M
Enterprise Value$12.98M
Share Statistics
Finch Therapeutics Group has 1,605,763 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,605,763
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Finch Therapeutics Group’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee107.00K
Profits Per Employee-74.75M
Employee Count1
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Finch Therapeutics Group is -0.08. Finch Therapeutics Group’s PEG ratio is <0.01.
PE Ratio-0.08
PS Ratio21.45
PB Ratio0.25
Price to Fair Value0.25
Price to FCF-0.18
Price to Operating Cash Flow-0.18
PEG Ratio<0.01
Income Statement
In the last 12 months, Finch Therapeutics Group had revenue of 107.00K and earned -74.75M in profits. Earnings per share was -46.59.
Revenue107.00K
Gross Profit-7.09M
Operating Income-34.00M
Pretax Income-78.22M
Net Income-74.75M
EBITDA-32.48M
Earnings Per Share (EPS)-46.59
Cash Flow
In the last 12 months, operating cash flow was -18.05M and capital expenditures 14.00K, giving a free cash flow of -18.04M billion.
Operating Cash Flow-18.05M
Free Cash Flow-18.04M
Free Cash Flow per Share-11.24
Dividends & Yields
Finch Therapeutics Group pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.85
52-Week Price Change443.10%
50-Day Moving Average14.10
200-Day Moving Average11.17
Relative Strength Index (RSI)39.73
Average Volume (3m)2.16K
Important Dates
Finch Therapeutics Group upcoming earnings date is May 9, 2024, TBA Not Confirmed.
Last Earnings DateMar 28, 2024
Next Earnings DateMay 9, 2024
Ex-Dividend Date―
Financial Position
Finch Therapeutics Group as a current ratio of 6.33, with Debt / Equity ratio of 203.88%
Current Ratio6.33
Quick Ratio6.33
Debt to Market Cap0.00
Net Debt to EBITDA―
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Finch Therapeutics Group has paid -3.46M in taxes.
Income Tax-3.46M
Effective Tax Rate0.04
Enterprise Valuation
Finch Therapeutics Group EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Finch Therapeutics Group has $16.04M in cash and marketable securities with $0.00 in debt, giving a net cash position of $12.95M billion.
Cash & Marketable Securities$16.04M
Total Debt$0.00
Net Cash$12.95M
Net Cash Per Share$8.07
Tangible Book Value Per Share$14.26
Margins
Gross margin is 95.11%, with operating margin of -31777.57%, and net profit margin of -69863.55%.
Gross Margin95.11%
Operating Margin-31777.57%
Pretax Margin-73098.13%
Net Profit Margin-69863.55%
EBITDA Margin-30357.01%
EBIT Margin-31777.57%
Analyst Forecast
The average price target for Finch Therapeutics Group is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-100.00%
EPS Growth Forecast89.80%